Richard Stanley Bedlack
Professor of Neurology
1. Investigator-initiated and multi-center clinical trials testing new treatments for amyotrophic lateral sclerosis and diabetic neuropathy.
2. Epidemiologic studies to better understand the causes and variability in prognosis of amyotrophic lateral sclerosis and diabetic neuropathy.
3. Basic science studies to develop novel biomarkers for amyotrophic lateral sclerosis.
2. Epidemiologic studies to better understand the causes and variability in prognosis of amyotrophic lateral sclerosis and diabetic neuropathy.
3. Basic science studies to develop novel biomarkers for amyotrophic lateral sclerosis.
Current Appointments & Affiliations
- Professor of Neurology, Neurology, Neuromuscular Disease, Neurology 2018
- Faculty Network Member of the Duke Institute for Brain Sciences, Duke Institute for Brain Sciences, University Institutes and Centers 2011
- Associate of the Duke Initiative for Science & Society, Duke Science & Society, Initiatives 2017
Contact Information
- 932 Morreene Rd Room234, Durham, NC 27705
- Duke Box 3333, Durham, NC 27710
-
bedla001@mc.duke.edu
(919) 668-2839
- Background
-
Education, Training, & Certifications
- EMG Fellow, Medicine, Duke University 1999 - 2000
- Neurology Resident, Medicine, Duke University 1996 - 1999
- Medical Intern, Medicine, Duke University 1995 - 1996
- M.D., University of Connecticut 1995
- Ph.D., University of Connecticut 1995
-
Previous Appointments & Affiliations
- Associate Professor of Neurology, Neurology, Neuromuscular Disease, Neurology 2011 - 2017
- Associate Professor of Medicine, Neurology, Clinical Science Departments 2006 - 2010
- Assistant Professor of Medicine, Neurology, Clinical Science Departments 2002 - 2006
- Associate in the Department of Medicine, Neurology, Clinical Science Departments 2000 - 2002
- Instructor, Temporary in the Department of Medicine, Neurology, Clinical Science Departments 2000
- Recognition
-
In the News
-
JAN 21, 2021 School of Medicine Magnify -
NOV 17, 2017 Duke Magazine -
MAY 23, 2017 Clinical Practice Today -
MAR 8, 2017 Duke Health News -
OCT 24, 2016 NPRs All Things Considered -
JUN 15, 2016 The Wall Street Journal -
NOV 16, 2015 The News & Observer -
AUG 13, 2015 -
AUG 13, 2015 ABC 11 -
AUG 13, 2015 Durham Herald-Sun -
FEB 20, 2015 WTVD -
NOV 18, 2014 -
AUG 29, 2014 -
APR 23, 2014 Ivanhoe Broadcast News -
MAR 10, 2014 The News & Observer
-
- Research
-
Selected Grants
- Healy ALS Platform study - Regimen E ¿ Trehalose TO#10 awarded by Massachusetts General Hospital 2021 - 2023
- Healey ALS Platform Trial Open Label Extension Zilucoplan awarded by Massachusetts General Hospital 2020 - 2023
- A PHASE 2B/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 MONTH CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MN-166 (IBUDILAST) FOLLOWED BY AN OPEN-LABEL EXTENSION IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS awarded by MediciNova, INC. 2020 - 2022
- Potential Role of the Gut Microbiome in ALS Progression and Reversals awarded by Augie's Quest to Cure ALS 2021 - 2022
- Potential Role of the Gut Microbiome in ALS Progression awarded by Martha Olson-Fernandez Foundation 2021 - 2022
- ALS Telemedicine awarded by Amyotrophic Lateral Sclerosis Association 2021 - 2022
- The Duke ALS Association Certified Center awarded by Amyotrophic Lateral Sclerosis Association 2018 - 2022
- I AM ALS awarded by Massachusetts General Hospital 2021
- Clinical Research in ALS & Related Disorders for Therapeutic Development (CREATE) awarded by University of Miami 2019 - 2021
- EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS: OPEN-LABEL EXTENSION FOR PATIENTS COMPLETING STUDY 3119002 awarded by Orion Corporation 2019 - 2021
- ALS Telemedicine awarded by Amyotrophic Lateral Sclerosis Association 2020 - 2021
- Identification of diagnostic peptides for the detection of sporadic amyotrophic lateral sclerosis (sALS) awarded by Affinergy, LLC 2020
- A Pilot Trial of Triheptanoin for People with Amyotrophic Lateral Sclerosis (PALS) awarded by Ultragenyx Pharmaceutical 2018 - 2020
- Duke ALS Telemedicine Clinic awarded by Amyotrophic Lateral Sclerosis Association 2018 - 2020
- Integrated Genomics in Clinical ALS (GTAC) awarded by Columbia University 2016 - 2019
- Protocol CY 5022: A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CK-2127107 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) awarded by Cytokinetics, Inc. 2017 - 2019
- Clinical Research in ALS & Related Disorders for Therapeutic Development (CREATE) awarded by University of Miami 2014 - 2019
- A Phase 2 Pharmacodynamic Study of Ezogabine on Neuronal Excitability in Amyotrophic Lateral Sclerosis awarded by GlaxoSmithKline 2015 - 2018
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation awarded by Neuraltus Pharmaceuticals, Inc 2016 - 2018
- A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY -ALS (CY 4031) awarded by Cytokinetics, Inc. 2016 - 2018
- A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerabiliity and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis ( ALS) awarded by Cytokinetics, Inc. 2015 - 2018
- HDE Post-Approval Study (PAS) of NeuRx DPS for ALS awarded by Synapse Biomedical, Inc 2013 - 2018
-
External Relationships
- AB Science
- ALS Association
- Adept Field Solutions
- Alexion
- Amylyx
- Apellis Pharmaceuticals
- Biogen Idec Inc.
- Brainstorm Cell
- Clearview Health Partners
- Clene Nanomedicine
- Corcept Therapeutics
- Cytokinetics, Inc.
- Genieus
- Guidepoint Global
- Health Advances
- ITF Pharma
- MJH Healthcare holdings
- Maple Health Care Group
- National Association of Managed Care Physicians
- New Biotic Inc
- Orphazyme
- Projects in Knowledge
- Shinkei Therapeutics
- The CM Group
- UCB Pharma
- WebMD health
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Mehta, Paul, Jaime Raymond, Moon Kwon Han, Theodore Larson, James D. Berry, Sabrina Paganoni, Hiroshi Mitsumoto, Richard Stanley Bedlack, and D Kevin Horton. “Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry's Research Notification Mechanism.” J Med Internet Res 23, no. 12 (December 7, 2021): e28021. https://doi.org/10.2196/28021.Full Text Link to Item
-
Bedlack, R. S., M. E. Cudkowicz, S. Paganoni, H. Khan-Tareen, and J. A. Andrews. “Accessing Investigational Products Outside of a Trial: Considerations for Neuromuscular Providers.” Current Treatment Options in Neurology 23, no. 12 (December 1, 2021). https://doi.org/10.1007/s11940-021-00697-x.Full Text
-
Oskarsson, Björn, Nicholas Maragakis, Richard S. Bedlack, Namita Goyal, Jenny A. Meyer, Angela Genge, Cynthia Bodkin, et al. “MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design.” Neurodegenerative Disease Management 11, no. 6 (December 2021): 431–43. https://doi.org/10.2217/nmt-2021-0042.Full Text
-
Bedlack, Richard, Sky Kihuwa-Mani, Paul E. Barkhaus, Michael Bereman, James B. Caress, Jesse Crayle, Gary L. Pattee, et al. “ALSUntangled 59: Tamoxifen.” Amyotroph Lateral Scler Frontotemporal Degener 22, no. 7–8 (November 2021): 595–98. https://doi.org/10.1080/21678421.2021.1876731.Full Text Link to Item
-
Bedlack, Richard, Paul E. Barkhaus, Benjamin Barnes, Morgan Beauchamp, Tulio Bertorini, Mark B. Bromberg, Gregory T. Carter, et al. “ALSUntangled #63: ketogenic diets.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, October 14, 2021, 1–5. https://doi.org/10.1080/21678421.2021.1990346.Full Text
-
Choi, Philip J., Michael Murn, Roberta Turner, and Richard Bedlack. “Continuing Non-Invasive Ventilation During Amyotrophic Lateral Sclerosis-Related Hospice Care Is Medically, Administratively, and Financially Feasible.” The American Journal of Hospice & Palliative Care 38, no. 10 (October 2021): 1238–41. https://doi.org/10.1177/1049909120982291.Full Text
-
Cudkowicz, Merit, Angela Genge, Nicholas Maragakis, Susanne Petri, Leonard van den Berg, Valtteri V. Aho, Toni Sarapohja, et al. “Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.” The Lancet. Neurology 20, no. 10 (October 2021): 821–31. https://doi.org/10.1016/s1474-4422(21)00242-8.Full Text
-
Galea, Marinella D., Vincent P. Galea, Adam C. Eberhart, Huned S. Patwa, Ileana Howard, Christina N. Fournier, and Richard S. Bedlack. “Infection rate, mortality and characteristics of veterans with amyotrophic lateral sclerosis with COVID-19.” Muscle & Nerve 64, no. 4 (October 2021): E18–20. https://doi.org/10.1002/mus.27373.Full Text
-
Li, Xiaoyan, and Richard Bedlack. “COVID-19-accelerated disease progression in two patients with amyotrophic lateral sclerosis.” Muscle & Nerve 64, no. 3 (September 2021): E13–15. https://doi.org/10.1002/mus.27351.Full Text
-
ALSUNTANGLED GROUP, Paul. “ALSUntangled #61: melatonin.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, May 18, 2021, 1–4. https://doi.org/10.1080/21678421.2021.1927103.Full Text
-
Mahoney, Colin J., Rebekah M. Ahmed, William Huynh, Sicong Tu, Jonathan D. Rohrer, Richard S. Bedlack, Orla Hardiman, and Matthew C. Kiernan. “Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis.” Cns Drugs 35, no. 5 (May 15, 2021): 483–505. https://doi.org/10.1007/s40263-021-00820-1.Full Text
-
ALSUNTANGLED GROUP, Paul. “ALSUntangled 57: Vinpocetine.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 22, no. 3–4 (May 2021): 316–19. https://doi.org/10.1080/21678421.2020.1786942.Full Text
-
Bedlack, Richard, Paul Barkhaus, Ben Barnes, Michael Bereman, Tulio Bertorini, Gregory Carter, Jesse Crayle, et al. “ALSUntangled #60: light therapy.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, March 8, 2021, 1–5. https://doi.org/10.1080/21678421.2021.1883668.Full Text
-
Berry, James D., Richard Bedlack, Debra Mathews, Wendy Agnese, and Stephen Apple. “Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 22, no. 1–2 (February 2021): 147–50. https://doi.org/10.1080/21678421.2020.1804939.Full Text
-
Crayle, Jesse, Mai Elmallah, John Sleasman, and Richard Bedlack. “Total serum immunoglobulin A in ALS.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 22, no. 1–2 (February 2021): 61–65. https://doi.org/10.1080/21678421.2020.1790608.Full Text
-
Wainger, Brian J., Eric A. Macklin, Steve Vucic, Courtney E. McIlduff, Sabrina Paganoni, Nicholas J. Maragakis, Richard Bedlack, et al. “Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.” Jama Neurology 78, no. 2 (February 2021): 186–96. https://doi.org/10.1001/jamaneurol.2020.4300.Full Text
-
Theunissen, Frances, Ryan S. Anderton, Frank L. Mastaglia, Loren L. Flynn, Samantha J. Winter, Ian James, Richard Bedlack, et al. “Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype.” Front Aging Neurosci 13 (2021): 658226. https://doi.org/10.3389/fnagi.2021.658226.Full Text Link to Item
-
Saez-Atienzar, Sara, Clifton L. Dalgard, Jinhui Ding, Adriano Chiò, Camile Alba, Dan N. Hupalo, Matthew D. Wilkerson, et al. “Identification of a pathogenic intronic KIF5A mutation in an ALS-FTD kindred.” Neurology 95, no. 22 (December 2020): 1015–18. https://doi.org/10.1212/wnl.0000000000011064.Full Text
-
ALSUntangled Group, Stephen. “ALSUntangled 56: "ten red flags"-things to be wary of in alternative or off-label products.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 21, no. 7–8 (November 2020): 642–47. https://doi.org/10.1080/21678421.2020.1765518.Full Text
-
Andrews, Jinsy A., James D. Berry, Robert H. Baloh, Nathan Carberry, Merit E. Cudkowicz, Brixhilda Dedi, Jonathan Glass, et al. “Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities.” Muscle Nerve 62, no. 2 (August 2020): 182–86. https://doi.org/10.1002/mus.26989.Full Text Link to Item
-
Brizzi, Kate T., John F. P. Bridges, Jill Yersak, Calaneet Balas, Neil Thakur, Miriam Galvin, Orla Hardiman, et al. “Understanding the needs of people with ALS: a national survey of patients and caregivers.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 21, no. 5–6 (August 2020): 355–63. https://doi.org/10.1080/21678421.2020.1760889.Full Text
-
Pytte, Julia, Loren L. Flynn, Ryan S. Anderton, Frank L. Mastaglia, Frances Theunissen, Ian James, Abigail Pfaff, et al. “Disease-modifying effects of an SCAF4 structural variant in a predominantly SOD1 ALS cohort.” Neurol Genet 6, no. 4 (August 2020): e470. https://doi.org/10.1212/NXG.0000000000000470.Full Text Link to Item
-
Bedlack, Richard, Allison Pogemiller, Jeremy Shefner, Merit Cudkowicz, and Terri Heiman-Patterson. “ALS clinical research learning institutes (ALS-CRLI): empowering people with ALS to be research ambassadors.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 21, no. 3–4 (May 2020): 216–21. https://doi.org/10.1080/21678421.2019.1690519.Full Text
-
Mitsumoto, Hiroshi, Diana C. Garofalo, Regina M. Santella, Eric J. Sorenson, Björn Oskarsson, J Americo M. Fernandes, Howard Andrews, et al. “Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 21, no. 3–4 (May 2020): 263–72. https://doi.org/10.1080/21678421.2020.1746810.Full Text
-
Fournier, Christina N., Richard Bedlack, Colin Quinn, James Russell, Diane Beckwith, Kathleen H. Kaminski, William Tyor, et al. “Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).” Jama Neurol 77, no. 4 (April 1, 2020): 480–88. https://doi.org/10.1001/jamaneurol.2019.4490.Full Text Link to Item
-
Pytte, Julia, Ryan S. Anderton, Loren L. Flynn, Frances Theunissen, Leanne Jiang, Ianthe Pitout, Ian James, et al. “Association of a structural variant within the SQSTM1 gene with amyotrophic lateral sclerosis.” Neurology. Genetics 6, no. 2 (April 2020): e406. https://doi.org/10.1212/nxg.0000000000000406.Full Text
-
Urbi, Berzenn, Simon Broadley, Richard Bedlack, Ethan Russo, and Arman Sabet. “Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.” Bmj Open 9, no. 11 (November 11, 2019): e029449. https://doi.org/10.1136/bmjopen-2019-029449.Full Text
-
Bedlack, Rick. “ALSUntangled 48: Perampanel (Fycompa).” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 20, no. 5–6 (August 2019): 453–56. https://doi.org/10.1080/21678421.2019.1573850.Full Text
-
Bedlack, R. S., Paul Wicks, Timothy Vaughan, Alicia Opie, Rebecca Blum, Amanda Dios, and Ghazaleh Sadri-Vakili. “Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial.” Amyotroph Lateral Scler Frontotemporal Degener 20, no. 3–4 (May 2019): 285–93. https://doi.org/10.1080/21678421.2018.1556698.Full Text Link to Item
-
Bedlack, Richard. “ALSUntangled No. 47: RT001.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 20, no. 3–4 (May 2019): 294–97. https://doi.org/10.1080/21678421.2018.1549531.Full Text
-
ALSUntangled Group, Richard, and Richard Bedlack. “ALSUntangled 46: penicillin G/hydrocortisone.” Amyotroph Lateral Scler Frontotemporal Degener 20, no. 1–2 (February 2019): 126–31. https://doi.org/10.1080/21678421.2018.1512704.Full Text Link to Item
-
Statland, Jeffrey M., Dan Moore, Yunxia Wang, Maureen Walsh, Tahseen Mozaffar, Lauren Elman, Sharon P. Nations, et al. “Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.” Muscle & Nerve 59, no. 2 (February 2019): 201–7. https://doi.org/10.1002/mus.26335.Full Text
-
Woolley, Susan, Ray Goetz, Pam Factor-Litvak, Jennifer Murphy, Jonathan Hupf, Diana C. Garofalo, Catherine Lomen-Hoerth, et al. “Corrigendum to "Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients".” Behavioural Neurology 2019 (January 2019): 6704740. https://doi.org/10.1155/2019/6704740.Full Text
-
Bedlack, Richard, and Richard ALSUntangled Group. “ALSUntangled 44: curcumin.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 19, no. 7–8 (November 2018): 623–29. https://doi.org/10.1080/21678421.2018.1440738.Full Text
-
Harrison, Daniel, Paul Mehta, Michael A. van Es, Elijah Stommel, Vivian E. Drory, Beatrice Nefussy, Leonard H. van den Berg, Jesse Crayle, Richard Bedlack, and Richard Pooled Resource Open-Access ALS Clinical Trials Consortium. “"ALS reversals": demographics, disease characteristics, treatments, and co-morbidities.” Amyotroph Lateral Scler Frontotemporal Degener 19, no. 7–8 (November 2018): 495–99. https://doi.org/10.1080/21678421.2018.1457059.Full Text Link to Item
-
ALSUNTANGLED GROUP, Pooled Resource Open Access A. L. S. “ALSUntangled 43: copper.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 19, no. 5–6 (August 2018): 472–76. https://doi.org/10.1080/21678421.2017.1406733.Full Text
-
Wolpaw, Jonathan R., Richard S. Bedlack, Domenic J. Reda, Robert J. Ringer, Patricia G. Banks, Theresa M. Vaughan, Susan M. Heckman, et al. “Independent home use of a brain-computer interface by people with amyotrophic lateral sclerosis.” Neurology 91, no. 3 (July 17, 2018): e258–67. https://doi.org/10.1212/WNL.0000000000005812.Full Text Link to Item
-
Bedlack, Richard, and Richard ALSUntangled Group. “ALSUntangled 42: Elysium health's "basis".” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 19, no. 3–4 (May 2018): 317–19. https://doi.org/10.1080/21678421.2017.1373978.Full Text
-
Earl, Damien E., Aaron I. Loochtan, and Richard S. Bedlack. “Refractory myasthenia gravis exacerbation triggered By pembrolizumab.” Muscle & Nerve 57, no. 4 (April 2018): E120–21. https://doi.org/10.1002/mus.26021.Full Text
-
Nicolas, Aude, Kevin P. Kenna, Alan E. Renton, Nicola Ticozzi, Faraz Faghri, Ruth Chia, Janice A. Dominov, et al. “Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.” Neuron 97, no. 6 (March 21, 2018): 1268-1283.e6. https://doi.org/10.1016/j.neuron.2018.02.027.Full Text Link to Item
-
ALSUntangled Group, Richard. “ALSUntangled 41: "Eric Is Winning".” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 19, no. 1–2 (February 2018): 157–60. https://doi.org/10.1080/21678421.2017.1350532.Full Text
-
Horton, D Kevin, Shannon Graham, Reshma Punjani, Grete Wilt, Wendy Kaye, Kimberly Maginnis, Lauren Webb, et al. “A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 19, no. 1–2 (February 2018): 126–33. https://doi.org/10.1080/21678421.2017.1406953.Full Text
-
Woolley, Susan, Ray Goetz, Pam Factor-Litvak, Jennifer Murphy, Jonathan Hupf, Diana C. Garofalo, Catherine Lomen-Hoerth, et al. “Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients.” Behavioural Neurology 2018 (January 2018): 5969137. https://doi.org/10.1155/2018/5969137.Full Text
-
Bedlack, Richard. “Perspective: Untangling the ALS X-Files.” Nature 550, no. 7676 (October 2017): S122. https://doi.org/10.1038/550s122a.Full Text
-
ALSUntangled Group, Shivanand P. “ALSUntangled No. 37: Inosine.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 18, no. 3–4 (May 2017): 309–12. https://doi.org/10.1080/21678421.2016.1223270.Full Text
-
ALSUNTANGLED GROUP, G. R. P. “ALSUntangled No. 36: Accilion.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 18, no. 1–2 (February 2017): 142–47. https://doi.org/10.1080/21678421.2016.1215400.Full Text
-
ALSUntangled Group, Amyotrophic Lateral. “ALSUntangled 38: L-serine.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 18, no. 1–2 (February 2017): 148–51. https://doi.org/10.1080/21678421.2016.1250353.Full Text
-
Mukherjee, Nisha, Shan McBurney-Lin, Anthony Kuo, Richard Bedlack, and Henry Tseng. “Retinal thinning in amyotrophic lateral sclerosis patients without ophthalmic disease.” Plos One 12, no. 9 (January 2017): e0185242. https://doi.org/10.1371/journal.pone.0185242.Full Text
-
Nieves, Jeri W., Chris Gennings, Pam Factor-Litvak, Jonathan Hupf, Jessica Singleton, Valerie Sharf, Björn Oskarsson, et al. “Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis.” Jama Neurol 73, no. 12 (December 1, 2016): 1425–32. https://doi.org/10.1001/jamaneurol.2016.3401.Full Text Link to Item
-
ALSUntangled Group, Gregory T. “ALSUntangled No. 35: Hyperbaric Oxygen Therapy.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 17, no. 7–8 (October 2016): 622–24. https://doi.org/10.3109/21678421.2016.1172818.Full Text
-
“ALSUntangled No. 34: GM604.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 17, no. 7–8 (October 2016): 617–21. https://doi.org/10.3109/21678421.2016.1164940.Full Text
-
Lee, Caroline M., Jason D. Lee, Lisa D. Hobson-Webb, Richard S. Bedlack, and Joseph K. Salama. “Treatment of Thymoma-Associated Myasthenia Gravis With Stereotactic Body Radiotherapy: A Case Report.” Annals of Internal Medicine 165, no. 4 (August 2016): 300–301. https://doi.org/10.7326/l15-0469.Full Text
-
Bedlack, Richard S., Timothy Vaughan, Paul Wicks, Jamie Heywood, Ervin Sinani, Roger Selsov, Eric A. Macklin, David Schoenfeld, Merit Cudkowicz, and Alex Sherman. “How common are ALS plateaus and reversals?” Neurology 86, no. 9 (March 1, 2016): 808–12. https://doi.org/10.1212/WNL.0000000000002251.Full Text Link to Item
-
Murphy, Jennifer, Pam Factor-Litvak, Raymond Goetz, Catherine Lomen-Hoerth, Peter L. Nagy, Jonathan Hupf, Jessica Singleton, et al. “Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort.” Neurology 86, no. 9 (March 2016): 813–20. https://doi.org/10.1212/wnl.0000000000002305.Full Text
-
Karam, Chafic Y., Sabrina Paganoni, Nanette Joyce, Gregory T. Carter, and Richard Bedlack. “Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review.” Am J Hosp Palliat Care 33, no. 1 (February 2016): 84–92. https://doi.org/10.1177/1049909114548719.Full Text Link to Item
-
Bedlack, Richard S., Nanette Joyce, Gregory T. Carter, Sabrina Paganoni, and Chafic Karam. “Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.” Neurologic Clinics 33, no. 4 (November 2015): 909–36. https://doi.org/10.1016/j.ncl.2015.07.008.Full Text
-
Miller, Robert G., Gilbert Block, Jonathan S. Katz, Richard J. Barohn, Vidhya Gopalakrishnan, Merit Cudkowicz, Jane R. Zhang, et al. “Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.” Neurology(R) Neuroimmunology & Neuroinflammation 2, no. 3 (June 2015): e100. https://doi.org/10.1212/nxi.0000000000000100.Full Text
-
ALSUntangled Group, Herbert Kim. “ALSUntangled: introducing The Table of Evidence.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 16, no. 1–2 (March 2015): 142–45. https://doi.org/10.3109/21678421.2014.987476.Full Text
-
Cirulli, Elizabeth T., Brittany N. Lasseigne, Slavé Petrovski, Peter C. Sapp, Patrick A. Dion, Claire S. Leblond, Julien Couthouis, et al. “Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.” Science (New York, N.Y.) 347, no. 6229 (March 2015): 1436–41. https://doi.org/10.1126/science.aaa3650.Full Text
-
ALSUntangled Group, Richard. “ALSUntangled No. 29: MitoQ.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 16, no. 5–6 (January 2015): 427–29. https://doi.org/10.3109/21678421.2015.1050897.Full Text
-
Paganoni, Sabrina, Chafic Karam, Nanette Joyce, Richard Bedlack, and Gregory T. Carter. “Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis.” Neurorehabilitation 37, no. 1 (January 2015): 53–68. https://doi.org/10.3233/nre-151240.Full Text
-
ALSUntangled Group, Gregory T. “ALSUntangled No. 26: lunasin.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 15, no. 7–8 (December 2014): 622–26. https://doi.org/10.3109/21678421.2014.959297.Full Text
-
Mitsumoto, Hiroshi, Pam Factor-Litvak, Howard Andrews, Raymond R. Goetz, Leslie Andrews, Judith G. Rabkin, Martin McElhiney, et al. “ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 15, no. 3–4 (June 2014): 192–203. https://doi.org/10.3109/21678421.2013.864312.Full Text
-
Rabourn, Jess, and Richard S. Bedlack. “SAPs: a different perspective.” The American Journal of Bioethics : Ajob 14, no. 11 (January 2014): 19–20. https://doi.org/10.1080/15265161.2014.957621.Full Text
-
ALSUntangled Group, Martin R., Christina Fournier, Bedlack Bedlack, Orla Hardiman, Terry Heiman-Patterson, Laurie Gutmann, Mark Bromberg, et al. “ALS Untangled No. 20: the Deanna protocol.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 14, no. 4 (May 2, 2013): 319–23. https://doi.org/10.3109/21678421.2013.788405.Full Text
-
Chad, David A., Lewis P. Rowland, Carmel Armon, Richard Bedlack, Heather Durham, Pam Factor-Litvak, Terry Heiman-Patterson, et al. “Peer recommendations on how to improve clinical research, and Conference wrap-up.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 14 Suppl 1 (May 2013): 67–73. https://doi.org/10.3109/21678421.2013.778605.Full Text
-
Sherman, Alexander V., Amelie K. Gubitz, Ammar Al-Chalabi, Richard Bedlack, James Berry, Robin Conwit, Brent T. Harris, et al. “Infrastructure resources for clinical research in amyotrophic lateral sclerosis.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 14 Suppl 1 (May 2013): 53–61. https://doi.org/10.3109/21678421.2013.779058.Full Text
-
Pastula, Daniel M., Dan H. Moore, and Richard S. Bedlack. “Creatine for amyotrophic lateral sclerosis/motor neuron disease.” The Cochrane Database of Systematic Reviews 12 (December 12, 2012): CD005225. https://doi.org/10.1002/14651858.cd005225.pub3.Full Text
-
ALSUntangled Group, Jiaoti. “ALS untangled No. 17: "when ALS is lyme".” Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 13, no. 5 (September 2012): 487–91. https://doi.org/10.3109/17482968.2012.717796.Full Text
-
Scherer, Katalin, and Richard S. Bedlack. “Diaphragm pacing in amyotrophic lateral sclerosis: a literature review.” Muscle & Nerve 46, no. 1 (July 2012): 1–8. https://doi.org/10.1002/mus.23419.Full Text
-
ALSUntangled Group, Dale P. “ALSUntangled No. 16: cannabis.” Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 13, no. 4 (June 2012): 400–404. https://doi.org/10.3109/17482968.2012.687264.Full Text
-
Kamel, Freya, David M. Umbach, Richard S. Bedlack, Marie Richards, Mary Watson, Michael C. R. Alavanja, Aaron Blair, Jane A. Hoppin, Silke Schmidt, and Dale P. Sandler. “Pesticide exposure and amyotrophic lateral sclerosis.” Neurotoxicology 33, no. 3 (June 2012): 457–62. https://doi.org/10.1016/j.neuro.2012.04.001.Full Text Link to Item
-
ALSUntangled Group, ALSUntangled. “ALSUntangled 15: coconut Oil.” Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 13, no. 3 (May 2012): 328–30. https://doi.org/10.3109/17482968.2012.671629.Full Text
-
Caulfield, Timothy, Amy Zarzeczny, and Amy Toronto Stem Cell Working Group. “Stem cell tourism and Canadian family physicians.” Canadian Family Physician Medecin De Famille Canadien 58, no. 4 (April 2012): 365-e185.
-
Bedlack, Richard S. “Compassionate use of stem cells for ALS: popovers and hot air.” Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 12, no. 5 (September 2011): 313–14. https://doi.org/10.3109/17482968.2011.583743.Full Text
-
Donofrio, Peter D., and Richard Bedlack. “Historical controls in ALS trials: a high seas rescue?” Neurology 77, no. 10 (September 2011): 936–37. https://doi.org/10.1212/wnl.0b013e31822cfcb6.Full Text
-
Bedlack, Richard S., Angela Genge, Anthony A. Amato, Aziz Shaibani, Carlayne E. Jackson, John T. Kissel, Cheryl Wall, et al. “Correspondence regarding: TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010:69;918-29.” Journal of Neuropathology and Experimental Neurology 70, no. 1 (January 2011): 96–97. https://doi.org/10.1097/nen.0b013e318204782b.Full Text
-
Simmons, Bryan J., Todd J. Cohen, Richard Bedlack, and Tso-Pang Yao. “HDACs in skeletal muscle remodeling and neuromuscular disease.” Handbook of Experimental Pharmacology 206 (January 2011): 79–101. https://doi.org/10.1007/978-3-642-21631-2_5.Full Text
-
Bedlack, Richard S., Paul Wicks, James Heywood, and Edward Kasarskis. “Modifiable barriers to enrollment in American ALS research studies.” Amyotroph Lateral Scler 11, no. 6 (December 2010): 502–7. https://doi.org/10.3109/17482968.2010.484494.Full Text Link to Item
-
Bedlack, Richard S. “Amyotrophic lateral sclerosis: current practice and future treatments.” Current Opinion in Neurology 23, no. 5 (October 2010): 524–29. https://doi.org/10.1097/wco.0b013e32833c7ac2.Full Text
-
Schellenberg, Kerri, Richard Bedlack, and Debara Tucci. “Roaring in the ears: patulous Eustachian tube in bulbar amyotrophic lateral sclerosis.” Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 11, no. 4 (August 2010): 395–96. https://doi.org/10.3109/17482960903501931.Full Text
-
Pastula, Daniel M., Dan H. Moore, and Richard S. Bedlack. “Creatine for amyotrophic lateral sclerosis/motor neuron disease.” The Cochrane Database of Systematic Reviews, no. 6 (June 16, 2010): CD005225. https://doi.org/10.1002/14651858.cd005225.pub2.Full Text
-
Khishchenko, Natan, Kelli D. Allen, Cynthia J. Coffman, Edward J. Kasarskis, Jennifer H. Lindquist, Joel C. Morgenlander, Barbara B. Norman, et al. “Time to diagnosis in the National Registry of Veterans with Amyotrophic Lateral Sclerosis.” Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 11, no. 1–2 (January 2010): 125–32. https://doi.org/10.3109/17482960802572681.Full Text
-
Pastula, Daniel M., Cynthia J. Coffman, Kelli D. Allen, Eugene Z. Oddone, Edward J. Kasarskis, Jennifer H. Lindquist, Joel C. Morgenlander, et al. “Factors associated with survival in the National Registry of Veterans with ALS.” Amyotroph Lateral Scler 10, no. 5–6 (October 2009): 332–38. https://doi.org/10.3109/17482960802320545.Full Text Link to Item
-
Qureshi, Muddasir, Richard S. Bedlack, and Merit E. Cudkowicz. “Lyme disease serology in amyotrophic lateral sclerosis.” Muscle & Nerve 40, no. 4 (October 2009): 626–28. https://doi.org/10.1002/mus.21438.Full Text
-
Bedlack, Richard S., Daniel M. Pastula, Jodi Hawes, and Debra Heydt. “Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease.” Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 10, no. 4 (August 2009): 210–15. https://doi.org/10.1080/17482960802430773.Full Text
-
Bedlack, Richard S., Vincenzo Silani, and Merit Ester Cudkowicz. “IPLEX and the telephone game: the difficulty in separating myth from reality on the internet.” Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 10, no. 3 (June 2009): 182–84. https://doi.org/10.1080/17482960802673059.Full Text
-
Bedlack, Richard, and Orla Hardiman. “ALSUntangled (ALSU): a scientific approach to off-label treatment options for people with ALS using tweets and twitters.” Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 10, no. 3 (June 2009): 129–30. https://doi.org/10.1080/17482960903015986.Full Text
-
Cudkowicz, Merit E., Patricia L. Andres, Sally A. Macdonald, Richard S. Bedlack, Rabia Choudry, Robert H. Brown, Hui Zhang, et al. “Phase 2 study of sodium phenylbutyrate in ALS.” Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 10, no. 2 (April 2009): 99–106. https://doi.org/10.1080/17482960802320487.Full Text
-
Bedlack, R. S., and S. Aggarwal. “Als update: Signs of progress, easons for hope.” Continuum Lifelong Learning in Neurology 15, no. 1 (January 1, 2009): 83–110. https://doi.org/10.1212/01.CON.0000300009.02717.a2.Full Text
-
Bedlack, Richard S., and Merit E. Cudkowicz. “Clinical trials in progressive neurological diseases. Recruitment, enrollment, retention and compliance.” Frontiers of Neurology and Neuroscience 25 (January 2009): 144–51. https://doi.org/10.1159/000209493.Full Text
-
Bedlack, Richard S., Daniel M. Pastula, Emily Welsh, Darlene Pulley, and Merit E. Cudkowicz. “Scrutinizing enrollment in ALS clinical trials: room for improvement?” Amyotroph Lateral Scler 9, no. 5 (October 2008): 257–65. https://doi.org/10.1080/17482960802195913.Full Text Link to Item
-
Rosenfeld, Jeffrey, Ruth M. King, Carlayne E. Jackson, Richard S. Bedlack, Richard J. Barohn, Arthur Dick, Lawrence H. Phillips, John Chapin, Deborah F. Gelinas, and Jau-Shin Lou. “Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.” Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 9, no. 5 (October 2008): 266–72. https://doi.org/10.1080/17482960802028890.Full Text
-
Gordon, Paul H., Ying-Kuen Cheung, Bruce Levin, Howard Andrews, Carolyn Doorish, Robert B. Macarthur, Jacqueline Montes, et al. “A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.” Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 9, no. 4 (August 2008): 212–22. https://doi.org/10.1080/17482960802195632.Full Text
-
Bedlack, Richard S., Nicholas Maragakis, and Terry Heiman-Patterson. “Lithium may slow progression of amyotrophic lateral sclerosis, but further study is needed.” Proceedings of the National Academy of Sciences of the United States of America 105, no. 16 (April 16, 2008): E17. https://doi.org/10.1073/pnas.0801762105.Full Text
-
Allen, K. D., E. J. Kasarskis, R. S. Bedlack, M. P. Rozear, J. C. Morgenlander, A. Sabet, L. Sams, et al. “The National Registry of Veterans with amyotrophic lateral sclerosis.” Neuroepidemiology 30, no. 3 (January 2008): 180–90. https://doi.org/10.1159/000126910.Full Text
-
Schmidt, Silke, Kelli D. Allen, Valerie T. Loiacono, Barbara Norman, Catherine L. Stanwyck, Kristina M. Nord, Christina D. Williams, et al. “Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis: the GENEVA study. Rationale, study design and demographic characteristics.” Neuroepidemiology 30, no. 3 (2008): 191–204. https://doi.org/10.1159/000126911.Full Text Link to Item
-
Gwinn, Katrina, Roderick A. Corriveau, Hiroshi Mitsumoto, Kate Bednarz, Robert H. Brown, Merit Cudkowicz, Paul H. Gordon, et al. “Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery.” Plos One 2, no. 12 (December 5, 2007): e1254. https://doi.org/10.1371/journal.pone.0001254.Full Text
-
Gordon, Paul H., Dan H. Moore, Robert G. Miller, Julaine M. Florence, Joseph L. Verheijde, Carolyn Doorish, Joan F. Hilton, et al. “Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.” Lancet Neurol 6, no. 12 (December 2007): 1045–53. https://doi.org/10.1016/S1474-4422(07)70270-3.Full Text Link to Item
-
Bedlack, Richard S., Bryan J. Traynor, and Merit E. Cudkowicz. “Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis.” Expert Opinion on Emerging Drugs 12, no. 2 (May 2007): 229–52. https://doi.org/10.1517/14728214.12.2.229.Full Text
-
Tabbarah, Khalid, John Madden, and Richard S. Bedlack. “Dysarthria and dysphagia from light chain amyloidosis.” Neurology 65, no. 10 (November 2005): 1671. https://doi.org/10.1212/01.wnl.0000182295.32791.e5.Full Text
-
Scherer, K., and R. S. Bedlack. “Working through the challenges of neuropathic pain.” Emergency Medicine 37, no. 10 (October 1, 2005): 37–43.
-
Bedlack, R. S., D. L. Simel, H. Bosworth, G. Samsa, B. Tucker-Lipscomb, and D. B. Sanders. “Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity.” Neurology 64, no. 11 (June 14, 2005): 1968–70. https://doi.org/10.1212/01.WNL.0000163988.28892.79.Full Text Link to Item
-
Scherer, Katalin, Richard S. Bedlack, and David L. Simel. “Does this patient have myasthenia gravis?” Jama 293, no. 15 (April 20, 2005): 1906–14. https://doi.org/10.1001/jama.293.15.1906.Full Text Link to Item
-
Bedlack, Richard S., Tuan Vu, Simon Hammans, Steven A. Sparr, Bennett Myers, Joel Morgenlander, and Michio Hirano. “MNGIE neuropathy: five cases mimicking chronic inflammatory demyelinating polyneuropathy.” Muscle & Nerve 29, no. 3 (March 2004): 364–68. https://doi.org/10.1002/mus.10546.Full Text
-
Burke, P., and R. S. Bedlack. “Diagnosing and stabilizing acute neuropathies.” Emergency Medicine 36, no. 1 (January 1, 2004): 15–27.
-
Bedlack, R. S., D. Edelman, J. W. Gibbs, D. Kelling, W. Strittmatter, A. M. Saunders, and J. Morgenlander. “APOE genotype is a risk factor for neuropathy severity in diabetic patients.” Neurology 60, no. 6 (March 2003): 1022–24. https://doi.org/10.1212/01.wnl.0000056689.50682.94.Full Text
-
Brewer, R., R. Bedlack, and E. Massey. “Erratum: Diabetic thoracic radiculopathy: An unusual cause of post-thoracotomy pain (Pain (2003) 105 (221-223)).” Pain 105, no. 3 (January 1, 2003): 509. https://doi.org/10.1016/j.pain.2003.09.001.Full Text
-
Armon, Carmel, Roberto J. Guiloff, and Richard Bedlack. “Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold.” Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 3, no. 3 (September 2002): 109–12. https://doi.org/10.1080/146608202760834094.Full Text
-
Bedlack, Richard S., and Donald B. Sanders. “On the concept of myasthenic crisis.” Journal of Clinical Neuromuscular Disease 4, no. 1 (September 2002): 40–42. https://doi.org/10.1097/00131402-200209000-00009.Full Text
-
Bedlack, Richard S., and Donald B. Sanders. “Steroid treatment for myasthenia gravis: steroids have an important role.” Muscle & Nerve 25, no. 1 (January 2002): 117–21. https://doi.org/10.1002/mus.1221.Full Text
-
Bedlack, R. S., W. J. Strittmatter, and J. C. Morgenlander. “Apolipoprotein E and neuromuscular disease: a critical review of the literature.” Archives of Neurology 57, no. 11 (November 2000): 1561–65. https://doi.org/10.1001/archneur.57.11.1561.Full Text
-
Bedlack, R. S., T. E. Bertorini, and D. B. Sanders. “Hidden afterdischarges in slow channel congenital myasthenic syndrome.” Journal of Clinical Neuromuscular Disease 1, no. 4 (June 2000): 186–90. https://doi.org/10.1097/00131402-200006000-00005.Full Text
-
Bedlack, R. S., and D. B. Sanders. “How to handle myasthenic crisis. Essential steps in patient care.” Postgraduate Medicine 107, no. 4 (April 2000): 211–22. https://doi.org/10.3810/pgm.2000.04.1003.Full Text
-
Ahearn, G. S., R. S. Bedlack, D. T. Price, C. N. Robertson, and J. C. Morgenlander. “Transient lumbosacral polyradiculopathy after prostatectomy: association with spinal stenosis.” Southern Medical Journal 92, no. 8 (August 1999): 809–11. https://doi.org/10.1097/00007611-199908000-00013.Full Text
-
Verma, A., R. S. Bedlack, R. A. Radtke, K. E. VanLandingham, and C. W. Erwin. “Succinylcholine induced hyperkalemia and cardiac arrest death related to an EEG study.” Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society 16, no. 1 (January 1999): 46–50. https://doi.org/10.1097/00004691-199901000-00004.Full Text
-
Bedlack, R. S., M. D. Wei, S. H. Fox, E. Gross, and L. M. Loew. “Distinct electric potentials in soma and neurite membranes.” Neuron 13, no. 5 (November 1994): 1187–93. https://doi.org/10.1016/0896-6273(94)90056-6.Full Text
-
Gross, E., R. S. Bedlack, and L. M. Loew. “Dual-wavelength ratiometric fluorescence measurement of the membrane dipole potential.” Biophys J 67, no. 1 (July 1994): 208–16. https://doi.org/10.1016/S0006-3495(94)80471-0.Full Text Link to Item
-
Bedlack, R. S., M. Wei, and L. M. Loew. “Localized membrane depolarizations and localized calcium influx during electric field-guided neurite growth.” Neuron 9, no. 3 (September 1992): 393–403. https://doi.org/10.1016/0896-6273(92)90178-g.Full Text
-
Mehta, Paul, Jaime Raymond, Moon Kwon Han, Theodore Larson, James D. Berry, Sabrina Paganoni, Hiroshi Mitsumoto, Richard Stanley Bedlack, and D Kevin Horton. “Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry’s Research Notification Mechanism (Preprint),” n.d. https://doi.org/10.2196/preprints.28021.Full Text
-
-
Conference Papers
-
Bedlack, Richard S., Daniel Pastuala, Elizabeth Welsh, Darlene Pulley, and Merit Cudkowicz. “Scrutinizing enrollment in ALS clinical trials: Room for improvement?” In Neurology, 70:A344–A344. LIPPINCOTT WILLIAMS & WILKINS, 2008.Link to Item
-
Bedlack, R. S., and S. Torres. “Multifocal motor neuropathy with upper motor neuron signs.” In Muscle & Nerve, 34:514–514. JOHN WILEY & SONS INC, 2006.Link to Item
-
Bedlack, R. S., D. Kelling, D. Edelman, J. W. Gibbs, W. Strittmatter, and J. Morgenlander. “Apolipoprotein E genotype is a risk factor for diabetic neuropathy.” In Annals of Neurology, 52:866–866. WILEY-LISS, 2002.Link to Item
-
Gross, E., R. S. Bedlack, and L. M. Loew. “Fluorescent imaging of membrane potential components.” In Analytical Use of Fluorescent Probes in Oncology, edited by E. Kohen and J. G. Hirschberg, 286:249–56. PLENUM PRESS DIV PLENUM PUBLISHING CORP, 1996.Link to Item
-
BEDLACK, R. S., M. D. WEI, S. FOX, E. GROSS, and L. M. LOEW. “ENDOGENOUS ELECTRIC-FIELDS WITHIN THE NEURONAL PLASMALEMMA - NONUNIFORMITIES SUGGESTING DIFFERENTIAL VOLTAGE-DEPENDENCE.” In Biophysical Journal, 66:A387–A387. BIOPHYSICAL SOCIETY, 1994.Link to Item
-
GROSS, E., R. S. BEDLACK, and L. M. LOEW. “DUAL-WAVELENGTH RATIOMETRIC FLUORESCENCE MEASUREMENT OF THE MEMBRANE DIPOLE POTENTIAL.” In Biophysical Journal, 66:A387–A387. BIOPHYSICAL SOCIETY, 1994.Link to Item
-
BEDLACK, R. S., M. D. WEI, and L. M. LOEW. “ELECTRIC FIELD-BIASED N1E-115 GROWTH CONE FILOPODIAL PROTRUSIONS ARE INHIBITED BY VERAPAMIL.” In Biophysical Journal, 64:A101–A101. BIOPHYSICAL SOCIETY, 1993.Link to Item
-
-
- Teaching & Mentoring
-
Recent Courses
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.
